Innovcare Lifesciences
Navi Mumbai, IN · 2 known investors
Innovcare Lifesciences markets and distributes branded nutraceutical and functional food products to healthcare practitioners across India for managing lifestyle-related disorders. The company operates a pan-India sales network and manufactures products through contract manufacturers meeting international WHO-cGMP standards.
Also known as Innovcare · Innovcare Lifesciences · Innovcare Lifesciences Private Limited · INNOVCARE LIFESCIENCES PRIVATE LIMITED · Innovcare Lifesciences Pvt. Ltd.
Investors · 2
Also in the syndicate · 1
Company profile
researched Aug 2026Innovcare Lifesciences Private Limited is a Mumbai-headquartered company operating in the nutraceutical, cosmeceutical and functional food categories. It markets and distributes branded products intended to address lifestyle-related disorders, organised around categories including bone and joint health, women's health, general health and sexual health, and supported by proprietary research in phytomedicine.
The company does not own manufacturing plants; it works with more than ten contract manufacturers at sites across India, selected and audited against WHO-cGMP standards. Its commercial focus areas span orthopedics, gynecology, diabetes, cardiology, sexology and general physicians. Its registered office is at 802, Vikas Center, Dr. C.G. Road, Chembur (E), Mumbai 400074, Maharashtra.
In June 2026 Sun Pharmaceutical Industries agreed to buy the entire issued and outstanding share capital of Innovcare Lifesciences in a cash transaction valued at about Rs2.71bn ($28.7m), with completion expected on or before 31 July 2026, after which Sun Pharma would hold full ownership and control.
Founding story
Innovcare Lifesciences was incorporated in 2014 in Navi Mumbai by Lalit Wadhawan, Dipin Varma, Chandan Rajmane and Vijay Dubey with the stated objective of providing research-backed healthcare solutions in the nutraceutical, cosmeceutical and functional food categories, addressing rising Indian demand for dietary supplements, sports nutrition and weight management products.
Business model
Innovcare markets, distributes and sells branded nutraceuticals, cosmeceuticals and functional foods in India. Production is outsourced to over ten contract manufacturers operating WHO-cGMP certified facilities, while the company retains brand ownership and the field sales organisation that promotes products to prescribers.
Revenue is generated from sales of branded nutraceutical, cosmeceutical and functional food products in India. Reported operating revenue was Rs809m in FY2023-24, Rs860m in FY2024-25 and Rs940m for the financial year ending March 2026. A separate database records total revenue of Rs87.7 Cr in FY25, up 6.6% year-on-year from Rs82.3 Cr, with a net loss of Rs2.2 Cr. The company has stated a target of at least $20 million in sales revenue.
Traction
The company reports over 400 sales executives covering more than 36,000 healthcare practitioners, more than ten contract manufacturing partners, and revenue rising from Rs809m (FY24) to Rs940m (FY ending March 2026). Employee headcount is reported at 190 by one data provider, while another profile lists a 501-1,000 band.
Latest developments
On 22 June 2026 it was reported that Sun Pharmaceutical Industries had agreed, per a regulatory filing, to acquire the entire share capital of Innovcare Lifesciences for approximately Rs2.71bn ($28.7m) in cash, with closing expected on or before 31 July 2026. Sun Pharma stated the deal was not a related-party transaction and required no governmental or regulatory approvals.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
The company positions itself in the Indian nutraceutical sector and states a vision of becoming India's leading nutraceutical company. It describes itself as having been recognised among the fastest-growing pharmaceutical companies in India, in a ranking band of 120 to 150. Sector context cited at the time of its 2019 financing put the Indian nutraceutical market at US$2.2 billion in 2015 with expected growth to US$6.1 billion by 2020 at over 20% CAGR.
The company emphasises phytomedicine-based formulations, an evidence review panel, WHO-cGMP certified contract manufacturing, and an executive team described as having a combined century of pharmaceutical and nutraceutical experience and backing from a private equity investor.
Technology
The company states it conducts proprietary research in phytomedicine and maintains an expert panel that reviews evidence for product formulations. Products are manufactured in third-party facilities audited to WHO-cGMP standards and tested for efficacy and potency during production.
Go-to-market
Distribution is prescription-led: a field force of more than 400 sales executives promotes the company's brands to over 36,000 healthcare practitioners across India, giving it a pan-India commercial footprint.
Healthcare practitioners in India across orthopedics, gynecology, diabetes, cardiology, sexology and general medicine, who prescribe or recommend the company's branded supplements to patients with lifestyle-related conditions.
Geography
Operations are focused on India. The head office is in Chembur, Mumbai, Maharashtra, with the company originally founded in Navi Mumbai; contract manufacturing sites and the sales organisation are spread across the country.
History
The company was founded in 2014 in Navi Mumbai, Maharashtra by Lalit Wadhawan, Dipin Varma, Chandan Rajmane and Vijay Dubey. In August 2019 it received a growth capital investment of US$6.4 million from JM Financial Private Equity Fund II, intended to fund expansion into new therapeutic areas and broaden the product portfolio. Within about six years of founding it had built a pan-India field force and practitioner reach. In June 2026, Sun Pharmaceutical Industries agreed to acquire the company for roughly $28.7 million in cash.
Risks & controversies
The company reported a net loss of Rs2.2 Cr in FY25 with total expenses of Rs89.2 Cr exceeding revenue of Rs87.7 Cr, a swing from the prior year. It depends on third-party contract manufacturers for all production and on a prescription-driven sales model. Reported figures differ across sources, including employee counts of 190 versus a 501-1,000 band and total funding of $5.6M versus $7.58M+.
Compiled by commissioned research from 13 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 6
launches, deals, and filingsSun Pharma agreed to purchase the entire issued and outstanding share capital of Innovcare Lifesciences in a cash transaction valued at about Rs2.71bn ($28.7m), with closing expected on or before 31 July 2026 and no governmental or regulatory approvals required.
$28.7M source ↗
Sun Pharmaceutical Industries entered a definitive agreement to buy the entire issued and outstanding share capital of Innovcare Lifesciences in an all-cash transaction valued at approximately Rs 271.2 crore ($28.7m), described as a strategic investment to strengthen its product portfolio. The deal is not a related-party transaction and requires no governmental or regulatory approvals; it is expected to close on or before 31 July 2026.
$28.7M source ↗
The company received $6.4m to strengthen and expand its nutraceutical portfolio, particularly for chronic ailments.
$6.4M source ↗
A market-data profile reports a Series D round on 7 October 2021 in which the company raised INR 150 million led by JM Financial Limited, with proceeds earmarked for product launches and market expansion.
A data provider lists 28 August 2019 as the company's most recent funding date, with total funding of $7.58m+ and a private equity funding stage.
Mumbai-based growth capital fund JM Financial Private Equity Fund II invested US$6.4 million in Innovcare Lifesciences to fund expansion into new therapeutic areas and augmentation of the product portfolio. O3 Capital and Economic Laws Practice advised on the deal.
$6.4M source ↗
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 13
primary sources listed
- Innovcareinnovcare.in · web
- Innovcare Lifesciences Pvt. Ltd. Asset Profile | Preqinpreqin.com · web
13 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Innovcare Lifesciences do?
- Indian nutraceutical company marketing branded phytomedicine-based supplements and functional foods to healthcare practitioners.
- Who are Innovcare Lifesciences's investors?
- Innovcare Lifesciences's investors include Kae Capital.
- Where is Innovcare Lifesciences headquartered?
- Innovcare Lifesciences is headquartered in Navi Mumbai, IN.